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Proper organ and tissue development requires a precise pattern of gene expression and repression 
as cells progress from proliferative states to terminal differentiation. In the normal development of 
skeletal muscle the transcription factor MyoD promotes muscle differentiation (myogenesis), binding 
at tens of thousands of sites across the genome and promoting histone acetylation (Cao, 2010). The 
myogenic activity of MyoD is opposed by several transcription factors including Musculin (MSC), 
which inhibits MyoD by occluding MyoD binding sites and by competing with MyoD for E-protein 
binding partners. In a recent study published in Skeletal Muscle, graduate student Kyle L. 
MacQuarrie, along with Drs. Zizhen Yao, Abraham P. Fong, and Stephen J. Tapscott of the Human 
Biology Division, determined that MSC binds broadly across the genome in a similar but non-
identical pattern to MyoD, suggesting that MSC may play a broad role in regulating MyoD activity 
during muscle development. 
Transcription factor binding patterns vary widely; some, like MyoD, bind broadly across the genome 
while others are restricted to binding only near the genes they regulate. However, it was unknown 
whether MSC, one of several MyoD transcriptional inhibitors, would bind at a subset of MyoD 
binding sites or more broadly.  To address this question, MacQuarrie, et al. employed a ChIP-seq 
approach and found that endogenous MSC binds genome-wide in a pattern very similar to MyoD. 
The team identified three types of binding sites: those shared between MyoD and MSC, sites that 
bound only one of the two proteins, and sites that overlapped but were not identical (see figure). 
While the binding patterns were broadly similar, MSC was slightly more enriched near transcription 
start sites. Motif analysis of the preferred binding site showed that MSC preferentially binds more 
GC-rich sequences than MyoD. Therefore, shared but non-identical binding sites may be explained 
by two E-boxes in close proximity that have different MyoD and MSC binding preferences. Similarly, 
the bias in MSC binding sites for increased GC content may explain the increased propensity for 
MSC to bind near transcription start sites, which tend to be GC-rich. 
MyoD binding induces histone acetylation to promote myogenesis; therefore the team asked 
whether MSC acts to inhibit MyoD by limiting histone acetylation. Paradoxically, MacQuarrie, et al.  
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found that histone acetylation was enriched at MSC binding sites. However, these MSC binding sites 
did not correlate with differential gene regulation. Furthermore, MSC binding tended to occur in 
DNAse hypersensitive regions, suggesting that the increased association of MSC is due to binding 
open, accessible chromatin rather than modifying histones. In addition, MSC binding site sequence 
recognition was less stringent than the requirements for MyoD binding, which may insure that MSC 
binding sites are less likely to be disrupted by mutation. 
Several muscle diseases, such as the pediatric cancer rhabdomyosarcoma, are the result of 
improper muscle differentiation. Therefore, it is essential to understand the complex interplay 
between transcription factors that promote and inhibit differentiation. "This study identifies MSC as 
having the capacity to widely affect the crucial action that MyoD plays in controlling muscle both in 
normal development and in disease. The more we understand the way that skeletal muscle cells 
behave on a fundamental level…the greater the chance we have to make advancements in treating 
the diseases that affect and involve skeletal muscle," said Kyle L. MacQuarrie. 
 
MacQuarrie KL, Yao Z, Fong AP, Tapscott SJ. 2013. Genome-wide binding of the basic helix-loop-
helix myogenic inhibitor musculin has substantial overlap with MyoD: implications for buffering 
activity. Skelet Muscle. Epub ahead of print. Doi:10.1186/2044-5040-3-26. 
 
See also: Cao Y, Yao Z, Sarkar D, Lawrence M, Sanchez GJ, Parker MH, MacQuarrie KL, Davison 
J, Morgan MT, Ruzzo WL, Gentleman RC, Tapscott SJ. 2010. Genome-wide MyoD binding in 
skeletal muscle cells: a potential for broad cellular reprogramming. Dev Cell. 18:662-74. 
 
 
 
 
 
 
 
December 16, 2013 SCIENCE SPOTLIGHT 
 
3 Volume 3, Issue 12 | Fred Hutchinson Cancer Research Center 
 
 
 
 
 
Image courtesy Kyle L. MacQuarrie 
Binding pattern of MyoD (top) or musculin (bottom) upstream of a troponin gene (TNNT2), 
demonstrating a similar but non-identical binding pattern for the two proteins. 
 
